The pharmaceutical industry is witnessing a significant shift from traditional dosage forms toward drug-device combination products (DDCPs), driven by the need for enhanced patient compliance, targeted drug delivery, and improved therapeutic outcomes. DDCPs integrate drugs with medical devices, offering novel delivery mechanisms that transcend the capabilities of conventional formulations. This article reviews the intellectual property landscape protecting DDCPs, highlighting the strategic importance of securing both drug and device patents to safeguard innovation. Regulatory considerations, with a focus on the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency, are examined, including key guidance documents, approval pathways, and compliance requirements. An overview of USFDA-approved devices used in DDCPs provides insights into current market trends and therapeutic applications. The article also outlines critical aspects of the design and development process for DDCPs, including material selection, device engineering, drug-device integration, and testing protocols. Finally, a business model framework is proposed for the successful design, development, and commercialization of DDCPs, emphasizing cross-functional collaboration, strategic partnerships, and early regulatory engagement. This comprehensive review aims to provide a foundational understanding for stakeholders interested in the evolving landscape of DDCPs.
Kumar KA, Bose PSC, Sathyanarayana MB, Vasantharaju SG, Ligade V, Amatha S, Osmani RA, Barwa R, Pawar SD, Ravi G. Strategic approaches for selecting regulatory pathways in drug-device combination products: A comprehensive review. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.244706
1. Office of Combination Products, Food and Drug Administration. Current good manufacturing practice requirements for combination products: guidance for industry and FDA staff. U.S. Department of Health and Human Services; 2017 [cited 2024 Aug 7]. Available from: http://www.fda.gov/oc/combination
2. European Union. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009, and repealing Council Directives 90/385/EEC and 93/42/EEC. Off J Eur Union. 2017 May 5;L 117/1 [cited 2024 Aug 7]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745
3. SKU: 47598710, GTIN: 00382904759872, BD: BD-100221, BD Hylok™ SCF 1MLL RF 7025/65 PP SHB. BD [Internet]. [cited 2024 Aug 7]. Available from: https://www.bd.com/en-in/products-and-solutions/products/product-page.47598710
4. Novo Nordisk Global. Pens and needles/NovoPen® 4 [Internet]. [cited 2024 Aug 7]. Available from: https://www.novonordisk.com/our-products/pens-and-needles/novopen-4.html
5. XIENCE Skypoint™ Stent. Abbott [Internet]. [cited 2024 Aug 7]. Available from: https://www.cardiovascular.abbott/us/en/hcp/products/percutaneous-coronary-intervention/xience-family/xience-skypoint.html
6. Ophthalmic Squeeze Dispenser (OSD) Technology Platform. Aptar [Internet]. [cited 2024 Aug 7]. Available from: https://aptar.com/products/pharmaceutical/ophthalmic-squeeze-dispenser-technology-platform/
7. HeroTracker®. Sense – digital solution for respiratory medicine. Aptar [Internet]. [cited 2024 Aug 7]. Available from: https://aptar.com/products/pharmaceutical/herotracker-sense-a-smart-healthcare-solution-for-digital-respiratory-medicine/
8. Jameel F, Skoug JW, Nesbitt RR, editors. Development of biopharmaceutical drug-device products. Berlin, Germany: Springer; 2020. doi: https://doi.org/10.1007/978-3-030-31415-6
9. Lauritsen KJ, Nguyen T. Combination products regulation at the FDA. Clin Pharmacol Ther. 2009;85(5):468–70. doi: https://doi.org/10.1038/clpt.2009.28
10. Reddy S, Beall RF, Tu SS, Kesselheim AS, Feldman WB. Patent challenges and litigation on inhalers for asthma and COPD: study examines patent challenges and litigation involving inhalers for asthma and COPD. Health Affairs. 2023;42(3):398–406. doi: https://doi.org/10.1377/hlthaff.2022.00873
11. Alhiary R, Kesselheim AS, Gabriele S, Beall RF, Tu SS, Feldman WB. Patents and regulatory exclusivities on GLP-1 receptor agonists. JAMA 2023;330(7):650–7. doi: https://doi.org/10.1001/jama.2023.13872
12. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations (orange book). 45th ed. Washington, DC: U.S. Department of Health and Human Services; 2025.
13. Demkowicz BJ, Tu SS, Kesselheim AS, Carrier MA, Feldman WB. Patenting strategies on inhaler delivery devices. Chest 2023;164(2):450–60. doi: https://doi.org/10.1016/j.chest.2023.02.031
14. U.S. Food and Drug Administration. Title 21, Code of Federal Regulations (CFR): part 210 - Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general [Internet]. Revised Apr 1, 2023 [cited 2024 Aug 7]. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210
15. U.S. Food and Drug Administration. Title 21, Code of Federal Regulations (CFR): part 211 - Current good manufacturing practice for finished pharmaceuticals [Internet]. Revised Apr 1, 2023 [cited 2024 Aug 7]. Available from:
16. U.S. Food and Drug Administration. Title 21, Code of Federal Regulations, Part 820: quality system regulation [Internet]. [cited 2024 Aug 7]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=820https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1688
17. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: http://accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1694
18. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1695
19. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2825
20. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2826
21. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR 868.5640 [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1305
22. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR 868.5630 [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=118
23. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR 868.5150 [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=82
24. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=145
25. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=163
26. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=920
27. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=953
28. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1029
29. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1267
30. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2703
31. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2704
32. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2705
33. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2706
34. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2737
35. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2739
36. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2817
37. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2830
38. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2842
39. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2863
40. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2880
41. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR 880.5860 [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2881
42. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2884
43. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2983
44. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR 880.5725 [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2997
45. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1117
46. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1141
47. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1154
48. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1155
49. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1156
50. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1170
51. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=1802
52. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=2415
53. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=3069
54. U.S. Food and Drug Administration. Product classification database [Internet]. [cited 2025 Feb 10]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=3073
55. Office of Device Evaluation, Food and Drug Administration. Applying human factors and usability engineering to medical devices: guidance for industry and FDA staff. February 2016 [cited 2025 Apr 24]. Available from: http://www.fda.gov/CombinationProducts/default.htm
56. Center for Devices and Radiological Health, Center for Drug Evaluation Research, Center for Biologics Evaluation and Research, and Office of Combination Products, Food and Drug Administration. Human factors studies and related clinical study considerations in combination product design and development: draft guidance for industry and FDA staff. February 2016 [cited 2025 Apr 24]. Available from: http://www.fda.gov/CombinationProducts/default.htm
57. Committee for Medicinal Products for Human Use (CHMP). Guideline on the quality requirements for drug-device combinations: draft guideline. EMA/CHMP/QWP/BWP/259165/2019. May 2019 [cited 2025 Apr 24]. Available from: https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_entity_is_document%3ADocument&search_api_fulltext=Draft%20guideline%20on%20the%20quality%20requirements%20for%20drug-device%20combinations%20-%20First%20version
58. Couto DS, Perez-Breva L, Saraiva P, Cooney CL. Lessons from innovation in drug-device combination products. Adv Drug Deliv Rev. 2012;64(1):69–77. doi: https://doi.org/10.1016/j.addr.2011.10.008
59. Choi SH, Wang Y, Conti DS, Raney SG, Delvadia R, Leboeuf AA, et al. Generic drug device combination products: regulatory and scientific considerations. Int J Pharm. 2018;544(2):443–54. doi: https://doi.org/10.101 6/j.ijpharm.2017.11.038
60. Burt HM, Hunter WL. Drug-eluting stents: a multidisciplinary success story. Adv Drug Deliv Rev. 2006;58(3):350–7. doi: https://doi.org/10.1016/j.addr.2006.01.014
61. Novo Nordisk Global, Smart Pens, Devices and Apps/NovoPen® 6 and NovoPen Echo® Plus. [cited 2025 May 16]. Available from: https://www.novonordisk.com/our-products/smart-pens/novopen-6.html
62. Medtronic News. Dated Sep 16, 2019. [cited 2025 May 16]. Available from:
63. Weissmann J, Mueller A, Messinger D, Parkin CG, Amann-Zalan I. Improving the quality of outpatient diabetes care using an information management system: results from the Observational VISION study. J Diabetes Sci Technol. 2015;9(2):244–50. doi: https://doi.org/10.1177/1932296815595984
64. Amgen Inc. Amgen annual report. 2021 [cited 2025 May 16]. Available from: https://www.amgen.com/investors
65. Wearable Bolus/High Volume Injectors. ONdrugDelivery September 14, 2015, Issue No 60. East Sussex, UK: Frederick Furness Publishing Ltd. [cited 2025 May 16]. Available from: https://www.ondrugdelivery.com/wp-content/uploads/2015/09/Wearable-Bolus-High-Volume-Injectors-ONdrugDelivery.pdf
66. Lilly Eli. Lilly initiates clinical trial to evaluate the functionality and safety of its automated insulin delivery system. December 2017 [cited 2025 May 16]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-initiates-clinical-trial-evaluate-functionality-and-safety
67. YpsoMed. SmartPilot for YpsoMate: reusable add-on transforms YpsoMate into a fully connected device. [cited 2025 May 16]. Available from: https://yds.ypsomed.com/en/products/autoinjectors/smartpilot-for-ypsomate.html
68. Fierce Biotec. Unilife inks 15-year deal with Sanofi for wearable injectors. By Joseph Keenan, Oct 7, 2014 8:56 am [cited 2025May 17]. Available from:
69. Injectable Drug Delivery. Issue No 120. Frederick Furness Publishing Ltd; May 31st 2021 [cited 2025 May 17]. Available from: https://www.ondrugdelivery.com/wp-content/uploads/2021/05/Injectable-Delivery-ONdrugDelivery-120-May- 2021-LR.pdf
70. Amgen press release. FDA approves first and only single monthly injection for A PCSK9 inhibitor. [cited 2025 May 17]. Available from: https://www.amgen.com/newsroom/press-releases/2016/07/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor
71. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34:3478–90.
72. Respiratory Therapy. AstraZeneca partners to develop smart inhaler adherence program. Therapy Devices; Aug 5, 2015 [cited 2025 May 17]. Available from: https://respiratory-therapy.com/products-treatment/monitoring-treatment/therapy-devices/astrazeneca-partners-develop-smart-inhaler-adherence-program/
73. Steinmetz JD, Seeher KM, Schiess N, Nichols E, Cao B, Servili C, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. 23(4):344–81. doi: https://doi.org/10.1016/S1474-4422(24)00038-3
74. Hershey A, Szperka CL, Barbanti P, Pozo-Rosich P, Bittigau P, Barash S, et al. Efficacy and safety of fremanezumab for the preventive treatment of episodic migraine in children and adolescents: a phase 3, randomised, double-blind, placebo-controlled study. Presented at European Headache Congress (EHC); 4-7 December 2024, Rotterdam. ePoster LP036.
75. Steinmetz JD, Seeher KM, Schiess N, Nichols E, Cao B, Servili C, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. In press.
76. Greene K, Irwin SL, Gelfand AA. Pediatric migraine: an update. Neurol Clin. 2019;37(4):815–33. doi: https://doi.org/10.1016/j. ncl.2019.07.009
77. GSK Press release archive. GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines. 01 August 2016 [cited 2025 May 17]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-and-verily-to-establish-galvani-bioelectronics-a-new-company-dedicated-to-the-development-of-bioelectronic-medicines/
78. Deena Beasley. Becton Dickinson to buy CareFusion for $12 billion in cash, stock. 2014 [cited 2025 May 17]. Available from: https://www.reuters.com/article/business/becton-dickinson-to-buy-carefusion-for-12-billion-in-cash-stock-idUSKCN0HU0U3/
79. CDER application number: 103471Orig1s5189. BETASERON®. Bayer HealthCare Pharmaceuticals Inc. [cited 2025 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/103471Orig1s5189.pdf
80. CDER application number: 207534Orig1s000. Symjepi™. Adamis Pharmaceuticals Corp. [cited 2025 May 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207534Orig1s0000MedR.pdf
81. Masierek M, Nabrdalik K, Janota O, Kwiendacz H, Macherski M, Gumprecht J. The review of insulin pens—past, present, and look to the future. Front Endocrinol (Lausanne). 2022 Mar 8;13:827484. doi: https://doi.org/10.3389/fendo.2022.827484
82. Nagai N. Evaluation of nanotechnology-based medicines. Tokyo: Pharmaceuticals and Medical Devices Agency (PMDA). [cited 2014 Oct 31]. Available from: https://ss.pmda.go.jp/en_all/search.x?nccharset=6A733F16&nccharset=FEF28A70&q=Neulasta&ie=UTF-8&page=1
83. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Introduction and methodology: standards of care in diabetes—2023. Diabetes Care 2023 Jan 1;46(Suppl 1):S1–4. doi: https://doi.org/10.2337/dc23-Sint
84. Pharmaceuticals and Medical Devices Agency (PMDA). List of approved medical devices. April 2004 to September 2024 [cited 2025 May 19]. Available from: https://www.pmda.go.jp/files/000274003.pdf
85. Pharmaceuticals and Medical Devices Agency (PMDA), Ministry of Health, Labour and Welfare of Japan. Strategy of SAKIGAKE. [cited 2025 May 20]. Available from: https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html
Year
Month